Vaxart
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (called "VAAST") include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus.

Vaxart has a collaborative development program for oral delivery of a vaccine against universal flu using proprietary antigens from Janssen Pharmaceutica (Janssen Vaccines and Prevention B.V.).
Q7108
biotechnology
Concept
Q134808
recombinant vaccine
Concept
Q1773974
prophylactic
Concept
Q1811185
enteric-coated
UNK
Q1142751
norovirus
Concept
Q4120645
seasonal influenza
Concept
Q1052913
respiratory syncytial virus
Concept
Q184627
human papillomavirus
Concept
Q103537
antigen
Concept
Q903523
Janssen Pharmaceutica
ORG
Q30292482
Vaxart
ORG
Q30292482
Vaxart
ORG
industry